Background
==========

Ethiopia stands among the world\'s top 22 tuberculosis (TB) high-burden countries, with an estimated annual incidence of 250 TB cases/10^5^population \[[@B1],[@B2]\]. In the Southern Ethiopia Regional State (SNNPRS), TB is among the leading causes for sickness and death \[[@B3]\]. As in many other resource-constrained settings, treatment outcomes for tuberculosis have not been satisfactory \[[@B4]\], mainly due to poor treatment compliance and low coverage of short course chemotherapy (SCC). Delays in the diagnosis and treatment initiation, the devastating HIV/AIDS epidemic and the potential threat of anti-tuberculosis drug resistance represent serious threats to the TB control effort in the region. The HIV co-infection among TB patients in the region is estimated at 19% \[[@B5]\].

Directly Observed Treatment, Short-course (DOTS) was introduced in the region in 1996. However, the impact of DOTS and its effectiveness in the regional context has not been assessed yet. Global reviews \[[@B6]\] and reports from Asian, African and East European countries \[[@B7]-[@B9]\] have favourable implications for the DOTS strategy. On the contrary, some randomised controlled studies have failed to establish the superiority of the most notable component of this strategy, direct observation of treatment, over the conventional non-observed treatment in improving treatment outcomes \[[@B10],[@B11]\]. Nevertheless, DOTS is widely accepted and practised, with some TB high-burden countries achieving almost full coverage of their populations \[[@B2]\]. DOTS is equally effective in curing TB patients with HIV co-infection \[[@B9],[@B12]\] and hence, its importance in the era of the HIV/AIDS epidemic.

With this study, we aimed to assess the results and trends in the expansion of DOTS in Hadiya Zone, Southern Ethiopia.

Methods
=======

Study setting
-------------

We did the study in Hadiya zone, Southern Ethiopia (see map in Figure [1](#F1){ref-type="fig"}), with a population of 1.2 million \[[@B13],[@B14]\]. In addition to fifteen diagnostic centres, five health centres and 21 health stations provide treatment for TB patients referred or transferred from the diagnostic centres, thus making the number of treatment centres 41. All treatment units have standard Unit Registers from the National Tuberculosis and Leprosy Control Programme (TLCP). TB drugs used in a combination of two or more in the region included isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E), streptomycin (S) and thioacetazone (T).

The TB and Leprosy control programs were run as two separate vertical programs funded and managed mainly by the All African Leprosy and Rehabilitation Training Centre (ALERT) until the end of 1996 when the National and Regional TLCP took over the responsibility. The zonal TLCP gets administrative and technical support from the regional TLCP, and monitors the activities in the diagnostic and treatment centres through its seven woreda (district) offices. The woreda health offices have standard district TB registers from the National TLCP, and are responsible for the distribution of drugs and reagents, supervision of day to day activities in the treatment units, collection of slides for quality control and record keeping. Quarterly reports on cases detected and treatment outcomes from the woredas are gathered at the zonal level and sent to the regional TLCP.

In 1994, only Hossana Hospital provided unobserved SCC for critically sick smear-positive pulmonary TB (PTB+), miliary TB and tuberculosis meningitis cases. DOTS was initiated in 1996 in two health facilities and gradually expanded, first to the health centres in all woredas and then to the health stations. Details of treatment regimens for various categories of patients under DOTS are given in the NTLCP manual \[[@B15]\]. In brief, all new patients were treated with SCC (two months on RHZ +/- E or S, followed by 6 months on EH or RH), and were required to take their medications under direct supervision by the health workers at least during the intensive phase of treatment. During this phase, only critically ill patients were hospitalised, while the rest received treatment on ambulatory basis. Re-treatment cases were treated with SERHZ for 2 months, ERHZ for 1 month and ERH for 5 months. In non-DOTS areas treatment with SCC was limited to critically sick PTB+, TB meningitis and miliary TB cases while others received LCC (two months on EH +/-S, followed by 10 months on EH; TH had also been used as an alternative to EH until its recent withdrawal).

Design and data collection
--------------------------

This is a retrospective trend analysis. The Unit Registers reviewed contain basic information such as patient\'s age, sex, address, category, TB type, drug regimen, date treatment started, treatment follow-up, follow-up sputum result and treatment outcomes.

We visited all 41 TB treatment centres during July-November 2002. We checked when DOTS was initiated in each health institution and looked for the availability of TB drugs and reagents during the time of visit. We then reviewed the Unit Registers and entered the data to the computer. At three peripheral treatment centres where the unit registers could not be found, the respective district TB registers were reviewed. For each TB case, we copied the data from the registers to a computer program, SPSS for windows \[[@B16]\], according to the standard definitions of the National TLCP \[[@B15]\] on disease classification, patient categories, treatment regimens and treatment outcomes. To ensure the quality of data entered into the computer database, two people independently cross-checked each entry.

Data analysis and Statistics
----------------------------

The data were analysed using SPSS for Windows version 11.0 \[[@B16]\]. For categorical data, we used proportions with 95% confidence intervals, Odds ratio and Chi-square test to compare different groups. Multivariate analysis using logistic regression model was used to analyse the association between treatment outcomes and potential predictor variables. We set the level of statistical significance at 5%.

Treatment outcomes were analysed for the years 1994--2000 because a considerable proportion of patients registered during 2001 were still on treatment during the time of data collection. (The Ethiopian fiscal year goes from July to June. Fiscal year 2001, for example, goes from July 2001 through June 2002, and our study was commenced in July 2002). Patients with unrecorded treatment outcome were analysed as defaulters.

Results
=======

Patient registration and case notification
------------------------------------------

A total of 19971 tuberculosis patients, 11138 (55.8%) males and 8819 (44.2%) females were registered between 1994 and 2001 with the mean (SD) age of 25.6 (13.2) years. Forty-six percent (n = 9232) of the patients were PTB+ cases. Overall, 18687 (93.6%) patients were registered as new cases, 558 (2.8%) as transferred in, 273 (1.4%) as return after default, 142 (0.7%) as failure and 139 (0.7%) as relapse cases whereas patient category was not recorded for 172 (0.9%) cases. Table [1](#T1){ref-type="table"} shows the general characteristics of the patients.

###### 

General Characteristics of the study subjects (n = 19971), 1994--2001

  **Characteristics**                     **Number**   **Percent**
  --------------------------------------- ------------ -------------
  ***Age group (years)***                              
   0--14                                  3356         16.8
   15--24                                 6262         31.4
   25--34                                 5366         26.9
   35--44                                 2706         13.5
   45--54                                 1248         6.2
   55--64                                 501          2.5
   ≥ 65                                   220          1.1
   Unknown                                312          1.6
  ***Sex***                                            
   Male                                   11138        55.8
   Female                                 8819         44.2
   Not mentioned                          14           0.1
  ***Patient Category***                               
   New                                    18687        93.6
   Transferred-in                         558          2.8
   Return after default                   273          1.4
   Failure                                142          0.7
   Relapse                                139          0.6
   Unknown                                172          0.9
  ***TB Classification***                              
   Pulmonary positive                     9232         46.2
   Pulmonary negative                     4225         21.2
   Extra-pulmonary                        6453         32.3
   Unknown                                61           0.3
  ***Treatment Centre***                               
   Hossana Hospital                       5362         26.8
   Lemmo district health facilities       4011         20.1
   Shashogo district health facilities    1208         6.0
   Misha district health facilities       2660         13.3
   Gibe district health facilities        1984         9.9
   Soro district health facilities        2313         11.6
   Duna district health facilities        216          1.1
   Badewacho district health facilities   2217         11.1

The proportion of women among TB patients registered for treatment remained at the range of 40--45% across the years and at the range of 43--47% across the age groups below 45. However, among patients older than 45 years, the proportion of women was significantly lower (31%; 95%CI 29--33) compared to those below 45 (46%; 95%CI 45--47).

Among new cases, 46% (n = 8557) were PTB+ patients. Except for the years 1997 (38%; 95%CI 36--40) and 2000 (56%; 95%CI 54--58), this proportion showed little variations in the range of 40--50%. Table [2](#T2){ref-type="table"} shows a trend in the case notification of PTB+ over the study period. The proportion of expected PTB+ incident cases notified increased from 45% in 1994 to 116% in 1999, and declined to 67% in 2001.

###### 

Trends in case notification of smear-positive pulmonary TB, Hadiya Zone, 1994--2001

  Year      Zonal Population\*   New PTB+ cases Reported (n = 8558)   Case Notification/ 10^5^persons/year   Proportion of estimated PTB+ incident cases notified, %\*\*
  --------- -------------------- ------------------------------------ -------------------------------------- -------------------------------------------------------------
  1994      1004000              512                                  49                                     45.2
  1995      1070160              1025                                 96                                     87.9
  1996      1101195              1162                                 106                                    96.8
  1997      1133129              946                                  84                                     76.6
  1998      1165990              1277                                 110                                    100.5
  1999      1199804              1510                                 126                                    115.5
  2000      1234598              1267                                 103                                    94.2
  2001^§^   1174118              858                                  73                                     67.0

\*Projected from the 1994 Population and Housing Census, CSA \[13\]

\*\*Estimated Incidence of PTB+ = 109/10^5^persons/year based on the WHO estimates of the Global Burden of Tuberculosis for 1997 \[1\]

^§^Population adjusted as an area with about 70--80 thousand population was taken away from Hadiya to the neighbouring Silti zone between years 2000 and 2001

PTB+: smear-positive pulmonary tuberculosis

Treatment given
---------------

Forty percent (n = 7919) of patients received SCC. Treatment regimen was not recorded for 981 (5%) cases. Table [3](#T3){ref-type="table"} presents trend in treatment regimens across the years by TB classification. The proportion of patients treated with SCC increased from 7% in 1994 to 58% in 1999, and 97% in 2001 (χ^2^~trend~, p \< 0.001).

###### 

Trend in treatment regimens for the different categories of patients (n = 19970).\*

  **Category**         **1994 n (%)**   **1995 n (%)**   **1996 n (%)**   **1997 n (%)**   **1998 n (%)**   **1999 n (%)**   **2000 n (%)**   **2001 n (%)**
  -------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **All TB cases**     1106             2201             2895             2742             3388             3253             2435             1950
  SCC                  73 (7)           311 (14)         288(10)          471 (17)         927 (27)         1881 (58)        2085 (86)        1883 (97)
  LCC                  1011 (91)        1684 (77)        2360 (82)        2097 (77)        2292 (68)        1302 (40)        304 (12)         20 (1)
  No record            22 (2)           206 (9)          247 (8)          174 (6)          169 (5)          70 (2)           46 (2)           47 (2)
                                                                                                                                              
  **New PTB+**         512              1025             1162             946              1277             1510             1267             858
  SCC                  9 (2)            111 (11)         94 (8)           232 (24)         537 (42)         1170 (78)        1187 (94)        837 (97)
  LCC                  496 (97)         780 (76)         938 (81)         611 (65)         660 (52)         321 (21)         68 (5)           7 (1)
  No record            7 (1)            134 (13)         130 (11)         103 (11)         80 (6)           19(1)            12 (1)           14 (2)
                                                                                                                                              
  **New PTB-**         258              385              402              382              807              772              487              393
  SCC                  12 (5)           66 (17)          90 (22)          109 (28)         225 (28)         395 (51)         402 (83)         379 (96)
  LCC                  242 (94)         286 (74)         248 (62)         251 (66)         543 (67)         362 (47)         73 (15)          \-
  No record            4 (1)            33 (9)           64 (16)          22 (6)           39 (5)           15 (2)           12 (2)           14 (4)
                                                                                                                                              
  **New EPTB**         257              668              1177             1176             1124             721              528              570
  SCC                  19 (8)           73 (11)          57 (5)           70 (6)           97 (9)           197 (27)         385 (73)         559 (98)
  LCC                  232 (90)         565 (85)         1081 (92)        1067 (91)        993 (88)         513 (71)         138 (26)         6 (1)
  No record            6 (2)            30 (4)           39 (3)           39 (3)           34 (3)           11 (2)           5 (1)            5 (1)
                                                                                                                                              
  **Relapse**          8                13               21               29               15               19               19               15
  SCC                  2 (25)           10 (77)          12 (57)          21 (72)          13 (87)          17 (90)          19 (100)         14 (93)
  LCC                  4 (50)           2 (15)           9 (43)           6 (21)           2 (13)           2 (10)           \-               \-
  No record            2 (2)            1 (8)            \-               2 (7)            \-               \-               \-               1 (7)
                                                                                                                                              
  **After default**    35               56               27               45               33               25               21               31
  SCC                  5 (14)           14 (25)          15 (56)          20 (45)          15 (46)          21 (84)          17 (81)          30 (97)
  LCC                  30 (86)          39 (70)          11(41)           23 (51)          18 (54)          4 (16)           4 (19)           \-
  No record            \-               3 (5)            1 (3)            2 (4)            \-               \-               \-               1 (3)
                                                                                                                                              
  **After failure**    28               38               17               17               13               19               8                2
  SCC                  26 (93)          35 (92)          15 (88)          13 (77)          11 (85)          14 (74)          8 (100)          2 (100)
  LCC                  2 (7)            3 (8)            2 (12)           4 (23)           2 (15)           5 (26)           \-               \-
  No record            \-               \-               \-               \-               \-               \-               \-               \-
                                                                                                                                              
  **Transferred in**   6                3                65               131              89               120              86               57
  SCC                  \-               \-               3 (5)            3 (2)            22 (25)          43 (36)          53 (62)          38 (67)
  LCC                  5 (83)           2 (67)           55 (84)          124 (95)         58 (65)          57 (47)          19 (22)          7 (12)
  No record            1 (17)           1 (33)           7 (11)           4 (3)            9 (10)           20 (17)          14 (16)          12 (21)
                                                                                                                                              
  **Missing info**     2                13               17               10               20               46               13               29
  SCC                  \-               2 (15)           1 (5)            3 (30)           3 (15)           11 (24)          9 (69)           29 (100)
  LCC                  \-               7 (54)           12 (71)          6 (60)           11 (55)          30 (65)          2 (16)           \-
  No record            2                4 (31)           4 (24)           1 (10)           6 (30)           5 (11)           2 (15)           \-

\* Percentages are out of the total cases registered in the same category during the year.

PTB+ = smear-positive pulmonary tuberculosis; PTB- = smear-negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis

SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)

LCC = long course chemotherapy (2 months on EH +/- S, followed by 10 months on EH; TH had also been used as an alternative to EH until its recent withdrawal).

R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.

During 1994--1997, more PTB- patents received SCC compared to PTB+ patients (19% vs. 12%; p \< 0.05) and EPTB patients (19% vs. 7%; p \< 0.05) among new cases of TB (Table [3](#T3){ref-type="table"}). This trend was reversed after 1997 when more PTB+ patients (76%) were put on SCC, followed by PTB- (57%) and EPTB (42%). There was no significant difference in the treatment regimens across the age groups and between the two sexes.

Follow-up
---------

Of the 8557 new PTB+ cases, sputum examination was repeated at the end of two months treatment for 60% (n = 5112), and 7.8% (n = 401) remained positive for AFB. At the end of five months treatment, 2747 (32%) patients had their sputum examined for AFB, and 78 (2.8%) remained smear-positive. 1823 (21%) patients had their sputum examined for AFB at (a month prior to) treatment completion, and 1.4% (n = 26) remained smear-positive. There has been a continuous and significant decline over time in the sputum positivity at two months irrespective of treatment regimen (Table [4](#T4){ref-type="table"}).

###### 

Trends in the follow-up smear results for new smear positive pulmonary tuberculosis

                        **2^nd^month**   **5^th^month**   End of treatment                         
  --------------------- ---------------- ---------------- ------------------ ---------- ---------- ----------
  **Cases on SCC**                                                                                 
  1994                  6 (67)           0                5 (56)             0          3 (33)     0
  1995                  79 (71)          18 (23%)         53 (48)            4 (8%)     33 (30)    0
  1996                  68 (72)          15 (22%)         38 (40)            2 (5%)     25 (27)    0
  1997                  155 (67)         14 (9%)          94 (41)            0          74 (32)    2 (3%)
  1998                  342 (64)         24 (7%)          183 (34)           0          140 (26)   0
  1999                  824 (70)         52 (6%)          411 (35)           7 (2%)     365 (31)   2 (0.5%)
  2000                  817 (69)         43 (5%)          439 (37)           9(2%)      316 (27)   2 (1%)
  2001^§^               527 (63)         13 (3%)          171 (20)           1 (0.6%)   121 (14)   0
  Cases on LCC                                                                                     
  1994                  330 (66)         45 (14%)         154 (31)           19 (12%)   86 (18)    5 (6%)
  1995                  508 (65)         75 (15%)         354 (45)           15 (4%)    179 (23)   4 (2%)
  1996                  564 (60)         59 (11%)         385 (41)           7 (2%)     223 (24)   4 (2%)
  1997                  302 (49)         15 (5%)          188 (31)           5 (3%)     86 (14)    3 (4%)
  1998                  263 (40)         19 (7%)          127 (19)           7 (6%)     80 (12)    2 (3%)
  1999                  182 (57)         7 (4%)           86 (27)            1 (1%)     68 (21)    2 (3%)
  2000                  46 (68)          1 (2%)           9 (13)             0          4 (6)      0
  2001^§^               2 (29)           1                2 (29)             0          1 (14)     0
  **Unknown regimen**                                                                              
  1994                  0                0                2 (29)             1          2 (29)     0
  1995                  9 (7)            0                4 (3)              0          3 (2)      0
  1996                  25 (19)          0                9 (7)              0          3 (2)      0
  1997                  23 (22)          0                11 (11)            0          3 (3)      0
  1998                  27 (34)          0                19 (24)            0          5 (6)      0
  1999                  4 (21)           0                1 (5)              0          1 (5)      0
  2000                  4 (33)           0                1 (8)              0          0          0
  2001^§^               5 (36)           0                17\)               0          2 (14)     0

sm+ = sputum smear positive for acid-fast bacilli out of examined.

SCC = short course chemotherapy; LCC = long course chemotherapy; AFB = acid-fast bacilli.

^§^Follow-up smears for the 5^th^month and end of treatment were not complete for the year 2001 as a considerable number of patients were still on treatment during the time of data collection.

Sputum positivity at the completion of fifth month treatment remained at the range of 0--2% for those on SCC, with the exception of 1995 and 1996 that exhibited 8% and 5% respectively. For those on LCC, smear positivity at 5^th^month decreased from 12% in 1994 to 1% in 1999. Overall, patients on LCC contributed more to the 5^th^month and end of treatment smear-positivity (treatment failure), than those on SCC (p \< 0.05; table [4](#T4){ref-type="table"}).

Treatment results
-----------------

We analysed treatment outcomes for the years 1994--2000 and, as a result, we evaluated 16943 (85% of the total) cases. Of these, 8268 (49%) successfully completed treatment, 3151 (18.6%) defaulted, 110(0.6%) had treatment failure, 446 (2.6%) died and 2000 (10%) were transferred out, while 2968 (17.5%) had no record of treatment outcomes. Assuming that patients with unrecorded treatment outcome had all defaulted from treatment, a total of 6119 (36.1%) patients defaulted.

Among new PTB+ (and all TB) patients, treatment success was higher among patients on SCC, while default and failure rates were higher among those on LCC (Table [5](#T5){ref-type="table"}). Death in all categories was higher among those on SCC. Among new cases on SCC, PTB+ cases had 1.8 (65% vs.37%) and 1.4 (65% vs. 48%) times higher rate of treatment success compared to PTB- and EPTB cases, respectively (p \< 0.001). Female PTB+ patients had significantly higher treatment success (58% vs. 54%; p = 0.001) and lower defaulter rate (26% vs. 30%; p \< 0.001) than males.

###### 

Treatment outcomes for different categories of patients on short and long course regimens (n = 16943)

                        **New cases**                                                        
  --------------------- --------------- ---------- ----------- --------- --------- --------- ----------
  **Patients on SCC**                                                                        
  Treatment success     2166 (65)       475 (37)   436 (48)    62 (66)   49 (46)   65 (53)   79 (64)
  Default\*             726 (22)        483 (37)   320 (36)    13 (14)   45 (42)   31 (25)   33 (26)
  Failure               25 (0.7)        \-         \-          2 (2)     1 (1)     6 (5)     3 (2)
  Death                 117 (3.5)       72 (5)     24 (3)      11 (12)   5 (5)     2 (1)     2 (2)
  Transferred out       306 (9)         269 (21)   118 (13)    6 (6)     7 (7)     18 (15)   7 (6)
                                                                                             
  **Patients on LCC**                                                                        
  Treatment success     1986 (51)       772 (39)   1932 (42)   14 (56)   32 (25)   11 (61)   189 (59)
  Default\*             1365 (35)       972 (48)   1922 (42)   8 (33)    79 (61)   2 (11)    24 (8)
  Failure               66 (2)          \-         \-          1 (4)     2 (2)     3 (17)    1 (0.3)
  Death                 107 (3)         57 (3)     37 (1)      2 (8)     2 (2)     1 (5)     7 (2)
  Transferred out       350 (9)         204 (10)   697 (15)    \-        14 (11)   1 (6)     3 (1)

\* Patients with missing treatment outcome information were assumed to have defaulted and analysed as defaulters.

PTB+ = smear positive pulmonary tuberculosis; PTB- = smear negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis

SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)

LCC = long course chemotherapy (2 months on EH +/-S, followed by 10 months on EH; TH had also been used as an alternative to EH until its recent withdrawal).

R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.

Patients registered as \"return after default\", had significantly lower treatment success compared to new cases, both for all TB (34% vs. 49%; p \< 0.001), and for PTB+ (34% vs. 58%; p \< 0.001). Furthermore, return after default cases were more likely to default again compared to new cases among PTB+ patients (53% vs. 29%; p \< 0.001) and all TB patients (53% vs. 36%; p \< 0.001). Treatment failure was five times higher among cases that received re-treatment for previous failure compared to new cases of PTB+ (6.4% vs. 1.2%; p \< 0.001); however, both groups had comparable treatment success, mainly due to a lower defaulter rate among failure cases (24% vs. 29%).

Patients for whom follow-up sputum smear remained positive at the second month during treatment had significantly lower treatment success than those with negative smear result (53% vs. 74%; p \< 0.001), mainly as a result of higher defaulter (24% vs. 18%) and failure (10% vs. 1%) rates among the former group.

Table [6](#T6){ref-type="table"} presents treatment outcomes for new cases of TB across the years. A steady rise in treatment success and decline in defaulter rate was noticed particularly among patients on SCC. Treatment failure showed a remarkable decline in both SCC and LCC groups. Death rate did not show much variation across the years.

###### 

Treatment outcomes across the years for new cases of tuberculosis

                       **1994 n (%)**   **1995 n (%)**   **1996 n (%)**   **1997 n (%)**   **1998 n (%)**   **1999 n (%)**   **2000 n (%)**
  -------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  PTB+ on SCC                                                                                                                
   Treatment success   5 (42)           40 (34)          45 (38)          122 (47)         338 (60)         811 (69)         805 (74)
   Default\*           5 (42)           61 (51)          50 (42)          77 (30)          114 (20)         225 (19)         194 (17)
   Failure             \-               3 (3)            2 (2)            2 (1)            \-               8 (1)            10 (1)
   Death               \-               4 (3)            2 (2)            10 (4)           24 (4)           44 (4)           33 (3)
   Transferred out     2 (17)           11 (9)           20 (17)          46 (18)          89 (16)          88 (7)           50 (5)
                                                                                                                             
  PTB+ on LCC                                                                                                                
   Treatment success   188 (38)         384 (48)         564 (56)         271 (45)         308 (52)         231 (72)         40 (68)
   Default\*           190 (38)         298 (38)         304 (30)         246 (40)         240 (40)         72 (22)          15 (25)
   Failure             23 (5)           18 (2)           8 (1)            8 (1)            6 (1)            3 (1)            \-
   Death               17 (3)           21 (3)           18 (2)           20 (3)           19 (3)           9 (3)            3 (5)
   Transferred out     78 (16)          71 (9)           107 (11)         63 (10)          24 (4)           6 (2)            1 (2)
                                                                                                                             
  PTB- on SCC                                                                                                                
   Treatment success   1 (8)            15 (23)          18 (20)          32 (29)          67 (30)          153 (39)         189 (47)
   Default\*           8 (67)           40 (60)          67 (74)          55 (50)          85 (38)          116 (29)         112 (28)
   Death               1 (8)            6 (9)            2 (2)            10 (9)           8 (4)            25 (6)           20 (5)
   Transferred out     2 (17)           5 (8)            3 (3)            12 (11)          65 (29)          101 (26)         81 (20)
                                                                                                                             
  PTB- on LCC                                                                                                                
   Treatment success   107 (44)         88 (31)          84 (34)          78 (31)          199 (37)         182 (50)         34 (47)
   Default\*           101 (42)         163 (57)         127 (51)         141 (57)         280 (51)         135 (37)         25 (34)
   Death               4 (2)            5 (2)            6 (2)            5 (2)            16 (3)           20 (6)           1 (1)
   Transferred out     30 (12)          30 (11)          31 (13)          27 (11)          48 (9)           25 (7)           13 (18)
                                                                                                                             
  EPTB on SCC                                                                                                                
   Treatment success   4 (21)           19 (26)          25 (44)          29 (32)          43 (44)          101 (51)         215 (56)
   Default\*           11 (58)          43 (59)          29 (51)          30 (33)          29 (30)          68 (35)          110 (28)
   Death               2 (11)           6 (8)            1 (2)            3 (4)            1 (1)            4 (2)            7 (2)
   Transferred out     2 (11)           5 (7)            2 (4)            28(31)           24 (25)          24 (12)          53 (14)
                                                                                                                             
  EPTB on LCC                                                                                                                
   Treatment success   80 (35)          274 (49)         559 (52)         387 (36)         341 (34)         222 (43)         69 (50)
   Default\*           122 (52)         203 (36)         321 (30)         412 (39)         553 (56)         253 (49)         58 (42)
   Death               2 (1)            3 (1)            3 (0.3)          7 (1)            8 (1)            14 (3)           \-
   Transferred out     28 (12)          85 (15)          198 (18)         260 (24)         91 (9)           24 (5)           11 (8)

\* Patients with missing information on treatment outcome were assumed to have defaulted and analysed as defaulters.

PTB+ = smear positive pulmonary tuberculosis; PTB- = smear negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis

SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)

LCC = long course chemotherapy (2 months on EH +/-S, followed by 10 months on EH; TH had also been used as an alternative to EH until its recent withdrawal).

R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.

When we adjusted the outcome measures for treatment results by various potentially confounding variables, significantly higher treatment success was exhibited among female patients, those 15--24 years, patients treated with SCC, those on re-treatment for relapse, PTB+ cases, those treated during 2000 and those treated in the Lemmo district health facilities (Table [7](#T7){ref-type="table"}). Meanwhile, male patients, patients aged 45--54, PTB- cases, those on LCC, return after default cases and those treated in Duna district health facilities exhibited significantly higher default rate.

###### 

Adjusted odds ratios for various factors that might affect treatment outcomes among registered tuberculosis patients

                              **Treatment success (all TB)**   **Default (all TB)**                                        
  --------------------------- -------------------------------- ---------------------- --------- ------ ------------------- ---------
  **Sex**                                                                                                                  
  Male                        45.5                             1.00                             37.5   1.00                
  Female                      49.4                             1.15(1.08--1.23)       \<0.001   34.0   0.88(0.82--0.94)    \<0.001
  **Age group (years)**                                                                                                    
  0--14                       42.6                             0.83 (0.75--0.92)      \<0.001   41.2   1.17 (1.06--1.30)   0.002
  15--24 (reference group)    51.1                             1.00                             33.4   1.00                
  25--34                      47.5                             0.84(0.77--0.91)       \<0.001   34.4   1.07 (0.98--1.17)   0.14
  35--44                      45.7                             0.76 (0.68--0.84)      \<0.001   36.1   1.14 (1.03--1.28)   0.02
  45--54                      44.9                             0.69 (0.60--0.79)      \<0.001   37.7   1.26 (1.09--1.46)   0.002
  55--64                      51.4                             1.04 (0.84--1.29)      0.71      35.4   1.04 (0.81--1.27)   0.90
  ≥ 65                        37.4                             0.67 (0.48--0.93)      0.02      43.7   1.27 (0.92--1.726   0.15
  **Patient category**                                                                                                     
  New                         47.0                             1.00                             35.9   1.00                
  Transferred-in              59.5                             1.09 (0.89--1.36)      0.40      35.7   1.19 (0.95--1.48)   0.13
  Return after default        33.9                             0.68 (0.51--0.92)      0.01      52.9   1.57 (1.19--2.07)   0.002
  Treatment failure           54.3                             1.30 (0.91--1.86)      0.15      23.6   0.72 (0.48--1.09)   0.12
  Relapse                     62.9                             1.51(1.01--2.26)       0.05      16.9   0.50 (0.30--0.82)   0.006
  **TB type**                                                                                                              
  Pulmonary positive          55.3                             1.00                             28.7   1.00                
  Pulmonary negative          37.5                             0.55 (0.50--0.60)      \<0.001   43.7   2.06 (1.87--2.26)   \<0.001
  Extra-pulmonary             42.4                             0.51 (0.47--0.55)      \<0.001   41.1   1.94 (1.78--2.11)   \<0.001
  **Treatment regimen**                                                                                                    
  Short course chemotherapy   55.5                             1.00                             27.7   1.00                
  Long course chemotherapy    45.0                             0.68 (0.62--0.75)      \<0.001   40.9   1.46 (1.33--1.61)   \<0.001
  **Treatment Centre\*\***                                                                                                 
  Hossana Hospital            27.0                             1.00                             40.0   1.00                
  Lemmo district HF           60.4                             5.14 (4.62--5.72)      \<0.001   20.6   0.28 (0.25--0.31)   \<0.001
  Shashogo district HF        50.8                             2.81 (2.41--3.28)      \<0.001   44.1   1.18 (1.01--1.37)   0.04
  Misha district HF           60.3                             4.78 (4.23--5.39)      \<0.001   33.0   0.58 (0.51--0.65)   \<0.001
  Gibe district HF            60.7                             4.78 (4.20--5.45)      \<0.001   26.2   0.51 (0.45--0.59)   \<0.001
  Soro district HF            50.5                             2.70 (2.39--3.06)      \<0.001   42.5   1.11 (0.98--1.26)   0.09
  Duna district HF            30.2                             0.77 (0.55--1.08)      0.12      67.3   5.18 (3.71--7.24)   \<0.001
  Badewacho district HF       41.1                             1.64 (1.44--1.86)      \<0.001   54.4   2.11 (1.86--2.40)   \<0.001
  **Year of treatment**                                                                                                    
  1994                        38.4                             1.00                             42.7   1.00                
  1995                        40.6                             1.18 (0.99--1.39)      0.06      39.9   1.17 (1.00--1.37)   0.05
  1996                        48.7                             1.29 (1.10--1.51)      0.002     33.3   0.83 (0.71--0.97)   0.02
  1997                        38.9                             0.72 (0.61--0.85)      \<0.001   39.5   1.08 (0.93--1.27)   0.32
  1998                        41.9                             0.74 (0.63--0.87)      \<0.001   43.8   1.20 (1.03--1.40)   0.02
  1999                        56.7                             1.37 (1.16--1.62)      \<0.001   30.0   0.59 (0.5--0.70)    \<0.001
  2000                        59.8                             1.41 (1.18--1.69)      \<0.001   25.8   0.54 (0.45--0.65)   \<0.001

OR = odds ratio; CI = confidence intervals; HF = Health facilities

\* All the variables in the table are included in the model.

\*\* All treatment centres in a district grouped together as a unit.

^1^Percentage out of total registered for treatment. Patients with missing outcome record were assumed to have defaulted and analysed as defaulters.

Trend over time
---------------

DOTS was initiated in 1996 in a hospital and one health centre, with potential population coverage of 25% (defined as population living within 2 hours walking distance from a health facility; estimated at 250,000 for the hospital and 25000 for the health centre). The number of health facilities providing DOTS increased to 10 in 1997, 30 in 1999 and 41 in 2001, making the population coverage by DOTS 31%, 58% and 75% respectively. The proportion of patients treated with SCC increased from 7% in 1994 to 27% in 1998, 58% in 1999, and 97% in 2001. 95% (39/41) of the treatment centres had at least isoniazid, rifampicin, pyrazinamide and ethambutol at the time of visit for data collection. Reagents for Acid-fast stain were available in nine of the 13 diagnostic centres functioning at the time.

Simultaneously, treatment success for new PTB+ patients (on SCC and LCC together) increased from 38% in 1994 to 56% in 1998, 70% in 1999 and 73% in 2000 (χ^2^~trend~, p \< 0.001). Defaulting among new PTB+ patients declined from 38% in 1994 to 30% in 1998, 20% in 1999 and 18% in 2000 (χ^2^~trend~, p \< 0.001). Treatment failure decreased from 5% in 1994 to 1% in 2000. The proportion of reported deaths remained unchanged over years with some variations in the range of 2--5%.

Treatment at small and large centres
------------------------------------

Thirty-one out of 40 (77.5%) peripheral treatment centres had significantly higher treatment success, and 28 (70%) of them had significantly lower defaulter rate compared to the zonal hospital (details not shown). Further comparison by districts revealed that six of the seven rural districts had significantly better treatment success while three out of seven had lower defaulter rate than the zonal hospital (Table [7](#T7){ref-type="table"}).

Discussion
==========

The results of our study show that there has been a continuous increase in treatment success and eventual decline in defaulter and failure rates in parallel to the expansion and decentralisation of DOTS to the lower treatment units. Treatment with SCC increased from a very low coverage in 1994 to almost full coverage in 2001 partly due to the expansion of DOTS (with SCC as one of its elements), and partly due to the regional TLCP commitment to SCC both in DOTS and non-DOTS areas. However, trends in case detection and notification showed inconsistencies over years.

In the hierarchy of study designs, observational studies come after the randomised controlled trials \[[@B17]\]. Nevertheless, in the real field condition, where randomised trials are not logistically feasible, such observational study designs may provide important and valid information. Our study design does not allow comparison of treatment outcomes between the DOTS and non-DOTS areas. However, this study gives us a valuable information on the program performance before and along the course of expanding DOTS in this resource-constrained rural setting.

Four years after the introduction of DOTS in the zone, it has been possible to achieve treatment success of 73% in 2000 for new PTB+ patients. Faring well towards the WHO/IUATLD recommended 85%, this confirms the finding of other studies \[[@B7],[@B18]\] that the DOTS strategy works well in resource-constrained settings with low overall health coverage. Increased coverage by SCC, improved access to care through decentralisation of the service and improved patient follow-up with the introduction of DOTS have most likely played a significant role in improving the treatment outcomes.

Higher treatment success and lower default among female patients confirms previous study findings \[[@B11]\]. However, the proportion of females among patients registered for TB treatment was found to be consistently low, and it was exceptionally lower among patients older than 45 years. This may reflect a genuine gender difference in the TB epidemiology \[[@B19]-[@B21]\]. However, the possibility of this being a reflection of gender differentials in access to health care within the society may need to be ruled out by further studies.

Patients treated at the peripheral treatment centres exhibited better treatment outcomes compared to those treated in the zonal hospital, which implies better follow-up of cases or better access to the TB care services.

Despite significant decline in defaulter rate over time, patients that received re-treatment as \"return after default\", were much more likely to default again compared to new patients. This group of defaulters seems refractory to the conventional approach of treatment supervision; social and cultural factors that might play a role need to be explored. More death among patients on SCC was an indication of the policy that severely sick patients and those co-infected with HIV be a priority for treatment by SCC and these groups were more likely than others to die. Though lower among patients on SCC, the high proportion of failure among patients retreated for previous failure might signal the emergence of multi-drug resistant TB (MDR-TB). Earlier studies have shown that MDR has so far been below 1% \[[@B22],[@B23]\].

The proportion of PTB+ was fairly stable in the range of 40--50% across the years, which indicates that the diagnosticians uniformly observed the diagnostic algorithms recommended by the NTLCP. The case detection rate (CDR), as estimated by the proportion of expected incident cases notified, showed an encouraging increase from 45% in 1994 to 115% in 1999, well above the CDR recommended by the WHO. The most plausible explanation for this might be that the vigorous implementation of the program during the earlier years of introduction of DOTS might have enabled detection of a big pool of prevalent cases of TB. But the pace in case detection could not be maintained during 2000 and 2001 when the CDR fell to 94% and 67% respectively. Reduction in the incidence of TB could be a possible explanation, but one cannot justify such a fast decline in a very short time. This calls for some case detection improvement initiatives to be in place as the proportion of TB cases detected and cured under DOTS is one of the health-related indicators of the millennium development goals \[[@B24]\]. Quality of the laboratory services and the possibility of under-reporting are among factors to be explored further.

Two major areas of program weakness need to be addressed. First, 94% of the patients were registered as new cases, which suggests that some re-treatment cases had been wrongly classified as new. Further, treatment outcomes have not been recorded for about one-fifth of the patients. Improving the record keeping system seems to be an immediate priority. Second, the proportion of PTB+ patients who had follow-up sputa examined for AFB was low. The threat of anti-TB drug resistance is imminent, and it is important to strengthen patient follow-up with sputum examinations. About one-third of the peripheral diagnostic facilities lacked reagents for Ziehl-Neelsen stain during the time of visit, and this might partly explain the low performance.

Conclusion
==========

The introduction and expansion of DOTS in Hadiya has led to a significant increase in treatment success and decrease in default and failure rates. The smaller institutions exhibited better treatment outcomes compared to the larger ones including the zonal hospital. The high number of patients with missing information in the unit registers is perhaps an issue that needs to be addressed as urgently as possible. Further studies are recommended to see the impact of the programme on the prevalence and incidence of tuberculosis.
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